# Role of Pre-operative Correction of Vitamin D3 Deficiency in Controlling Post-operative Bone Pain after Unicompartmental Knee Arthroplasty

Rajani AM¹, MS Orth, Mittal ARS¹, MS Orth, Kulkarni VU¹, MS Orth, Rajani KA², BSc, Rajani KA², BSc

<sup>1</sup>Department of Orthopaedics, Orthopaedic Arthroscopy Knee and Shoulder Clinic, Mumbai, India <sup>2</sup>Department of Clinical Research, Orthopaedic Arthroscopy Knee and Shoulder Clinic, Mumbai, India



This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Date of submission: 26th November 2022 Date of acceptance: 04th June 2024

### **ABSTRACT**

**Introduction:** Hypovitaminosis D plays an important role in post-operative bone pain and muscle strength in arthroplasty surgeries. Its role in unicompartmental knee arthroplasty (UKA) has not been elucidated yet. The objective of this study was to determine the impact of hypovitaminosis D and its correction on post-operative bone pain after UKA.

Materials and methods: A prospective cohort study involving 240 patients undergoing mobile-bearing medial UKA was conducted. Group A (na=80) received post-operative correction of Vitamin D₃ Deficiency (VDD), Group B (nb=80) received pre-operative correction of VDD, while Group C (nc=80) had normal Vitamin D₃ levels to begin with (≥₃0ng/ml). Correction was done by three doses of intramuscular injection of 600,000 IU Arachitol® (Vitamin D₃) given at an interval of one week each. All groups were matched for demography and outcome measures. The level of bone pain by checking for tibial shin tenderness quantified by the visual analog scale (VAS) and evaluated preoperatively, and at 2, 4, 6 and 12 weeks post-operatively.

**Results:** Group B and C showed similar post-operative trends and remained significantly superior to Group A till the 6th-week follow-up. The biostatistical difference between Group A and the other two groups started decreasing after the completion of post-operative correction regime as noticed on the 6th-week follow-up. By 12 weeks post-operatively, all three groups had similar levels of bone pain.

**Conclusion:** Vitamin D<sub>3</sub> serves as an important preoperative investigation in patients undergoing UKA as it is a modifiable risk factor affecting post-operative bone pain. Its correction pre-operatively gives excellent post-operative pain control.

### Keywords:

unicompartmental knee arthroplasty, vitamin D deficiency, vitamin D3, bone pain, shin tenderness

### INTRODUCTION

Vitamin D3 is a secosteroid produced in the skin in response to sunlight and regulates calcium and phosphate levels1. Levels of 25-Hydroxy Vitamin D<sub>3</sub> below 30ng/ml (<72.5nmol/L) are generally considered insufficient and below 20ng/mL (<50nmol/L) considered deficient<sup>2-3</sup>. Insufficiency is common due to limited sun exposure, poor dietary intake, rapid urbanisation, and high air pollution or as a consequence of gut malabsorption or failure to metabolise Vitamin D<sub>3</sub> to its active form<sup>4</sup>. Apart from its well-known role in the modulation of osseous and serum calcium and phosphate levels, Vitamin D<sub>3</sub> has an important role in perception of pain via the modulation of anti-inflammatory cytokines<sup>5</sup>. The prevalence of VDD has been reported to be as high as 59% in literature, with an increasing trend in the older age group6. This is of significance in patients undergoing surgery for degenerative conditions such as osteoarthritis of the knee joint wherein an 82% prevalence has been reported<sup>7</sup>. Although the causal role of low Vitamin D<sub>3</sub> on pain due to osteomalacia is well recognised, the combination of surgery and hypovitaminosis D may be further deleterious8. Studies have shown low or insufficient levels of Serum Vitamin D3 resulting in suboptimal recovery in patients undergoing total knee arthroplasty (TKA)9. Preoperative Serum Vitamin D<sub>3</sub> insufficiency was also proposed as a modifiable risk factor for moderate to severe, persistent pain after TKA in addition to poorer quality of life8,10. Hypovitaminosis D is also related to worse pain-related outcomes and quality of life10. Peri prosthetic infection and longer hospital stay have also been reported with VDD11. Apart from enzyme linked immunosorbent assay (ELISA) as a chemical method to measure Vitamin D3 levels, tibial bone tenderness can be used as a clinical sign for VDD<sup>12</sup>. Over the past decades, orthopaedic surgeons have made a constant effort to ameliorate bone pain after arthroplasty surgeries. Considering the rapidly increasing number of UKA procedures being done across the globe owing to its superior

results to TKA in patients with bone-on-bone medial compartment osteoarthritis (MCOA)<sup>13</sup>, the influence of VDD in such patients could be important.

The effect of VDD on post-operative bone pain after a UKA is still unknown, hence this study attempted to fill this lacuna by assessing the role of pre-operative VDD correction on post-operative bone pain by assessing the tibial shin tenderness and quantifying it using VAS scores in patients undergoing UKA. We hypothesised that pre-operative correction of VDD in such patients gives superior results in terms of bone pain control as compared to patients who underwent correction after the surgery and in the bigger picture, help in improving overall or recalcitrant pain. This will consequently help in establishing whether or not Vitamin D<sub>3</sub> is an important pre-operative investigation protocol for UKA in order to obtain better results.

### **MATERIALS AND METHODS**

This was a prospective cohort study including 240 consecutives, consenting patients who underwent primary UKA between 1st January 2020 and 31st March 2022, performed by a single surgeon at a single centre. All procedures that were followed were in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983. Informed written consent was taken from all the patients before including them in the study. The patients were recruited based on fixed inclusion and exclusion criteria. Patients clinically and radiologically diagnosed medial compartment osteoarthritis were counselled for the study and advised magnetic resonance imaging (MRI) (n=712). Patients with more than 10° of varus or 5° of valgus deformity, flexion contracture, or unwilling to participate in the study were excluded (ne=211). Patients diagnosed with lateral compartment osteoarthritis on MRI were advised total knee arthroplasty and excluded from study (ne=73). Further exclusions were patients undergoing revision surgery, patients on medications (antiepileptics, corticosteroids, immunosuppressive agents, chemotherapeutic agents, thiazides) or conditions (advanced kidney disease (eGFR <60mL/minute) or on dialysis support, hypercalcemia (total calcium >10.6mg/dL or ionized serum calcium >5.4mg/dL), nephrolithiasis, hyperparathyroidism, obesity/body mass index (BMI) of more than 30kg/m<sup>2</sup>) affecting vitamin D3 absorption and metabolism, patients already on Vitamin D3 supplements, patients having a known contraindication to Vitamin D<sub>3</sub> supplements such as hypersensitivity, or conditions that could confound the outcome of surgery such as granulomatous disease, previous infection/septic arthritis in the same joint, uncontrolled diabetes mellitus (HBA1c>8%), patients with neuromuscular disorders or prolapsed intervertebral disc (ne=177).

All the patients enrolled in the study were diagnosed as a case of MCOA knee by clinical examination and

radiologically using standard anteroposterior standing radiographs, lateral supine radiographs, and special radiographs such as Rosenberg posteroanterior view and Valgus stress anteroposterior view for correctability of varus deformity. The demographic data of all the patients was collected and compiled. All these patients were also evaluated pre-operatively for bone pain by clinically assessing VDD by assessing for tibial shin tenderness. Visual analog scale (VAS) was used for pain evaluation<sup>14,15</sup>. Preoperative levels of Serum Vitamin D3 were calculated using the Electrohemiluminescence Immunoassay method from the same diagnostic centre (blinded) and samples collected early morning after overnight fasting. The cut-off for VDD in our study was kept at 30ng/ml<sup>3</sup>. Patients with VDD who were scheduled for surgery ≤30 days from their index consultation underwent post-operative correction of Vitamin D<sub>3</sub> levels and were allocated Group A (na=80). Those scheduled for surgery >30 days from their index consultation underwent pre-operative correction of the VDD and were classified as Group B (nb=80). Group C (nc=80) included patients with normal Vitamin D3 levels from the outset on pre-operative testing and operated within a month of evaluation. The three groups were matched for age, gender, BMI, dominant side, comorbidities (including medications), and socioeconomic status (according to the modified Kuppuswamy scale)16. Correction was done by three doses of injection Arachitol® 600,000 IU (Abbott Healthcare Products BV) given intramuscularly (IM) once a week for three weeks based on the experience of the chief surgeon (Fig. 1, Fig. 2).

All the 240 patients enrolled in the study underwent UKA by mobile bearing Oxford knee arthroplasty by the same surgeon, at the same centre, under spinal anaesthesia. Paramedian incision and mini mid-vastus approach<sup>17</sup> was used and all patients had a similar incision size of about 8cm with minimal soft tissue insult and use of cautery. All the individuals in group A and group B had post-operative bone pain assessed by severity of shin tenderness which was attributed to deficient serum Vitamin D3 levels despite of the fact that all the individuals enrolled in this study were given the same analgesics and anti-inflammatory medications postoperatively for a period of one week only. Similar preoperative, intra-operative, and post-operative protocols were followed strictly. On the day of the surgery, intravenous paracetamol 1gm was given at 8-hour interval to all patients. From day one post-surgery, patients were started on the oral etoricoxib regimen (60mg TDS) till post-operative day seven. All patients underwent the same rehabilitation protocol with mobilisation using walker from the day of the surgery. Correction of VDD in Group A was done postoperatively starting from the night after the surgery.

Post-operative assessment was done by a blinded clinician at 2,4,6 and 12 weeks after the surgery by documenting the VAS score for shin tenderness (Fig. 2). No patient was lost to follow-up. All of the data was compiled and computed on the

**Table I:** Baseline demographic and clinical data of patients in Group A (Corrected after surgery), Group B (Corrected before surgery) and Group C (No Vitamin D deficiency).

| Variables                            | Group A      | Group B      | Group C          | Overall      |
|--------------------------------------|--------------|--------------|------------------|--------------|
|                                      | <u> </u>     | •            | •                |              |
| Number of patients (n)               | 80           | 80           | 80               | 240          |
| Mean Age (years)                     | 64.34 ± 8.54 | 65.46 ± 8.20 | $64.62 \pm 8.20$ | 64.8 ± 8.29  |
| Gender                               |              |              |                  |              |
| Males                                | 29 (36.3%)   | 28 (35%)     | 29 (36.3%)       | 86 (35.83%)  |
| Females                              | 51 (63.7%)   | 52 (65%)     | 51 (63.7%)       | 154 (64.17%) |
| Side affected                        |              |              |                  |              |
| Dominant                             | 41 (51.25%)  | 40 (50%)     | 42 (52.5%)       | 123 (51.25%) |
| Non-dominant                         | 39 (48.75%)  | 40 (50%)     | 38 (47.5%)       | 117 (48.75%) |
| Mean Body Mass Index (kg/m2)         | 27.24±2.38   | 26.8±2.97    | 27.15±2.04       | 27.06±2.48   |
| Pre-operative Vitamin D (ng/ml)      | 16.8±6.08    | 51.02±6.45   | 48.6±7.32        | 38.81±6.62   |
| 12 weeks follow-up Vitamin D (ng/ml) | 52.37±6.74   | 50.48±6      | 47.95±7.18       | 50.26±19.92  |
| Comorbidities (on medication)        |              |              |                  |              |
| Hypertension                         | 24 (30%)     | 22 (27.5%)   | 22 (27.5%)       | 68 (28.33%)  |
| Diabetes Melltitus (HBA1c<8%)        | 4 (5%)       | 6 (7.5%)     | 3 (3.75%)        | 13 (5.42%)   |
| Hypothyroidism                       | 2 (2.5%)     | 1 (1.25%)    | 2 (2.5%)         | 5 (2.08%)    |
| Ischemic Heart disease               | 2 (2.5%)     | 3 (3.75%)    | 3 (3.75%)        | 8 (3.33%)    |
| Anxiety/ Depression                  | 1 (1.25%)    | 1 (1.25%)    | 1 (1.25%)        | 3 (1.25%)    |
| Socioeconomic status                 | . (          | . ()         | . (5,0)          | 5 (112570)   |
| (Modified Kuppuswamy scale)          |              |              |                  |              |
| Upper                                | 17 (21.25%)  | 15 (18.75%)  | 16 (20%)         | 58 (24.17%)  |
| Upper middle                         | 16 (20%)     | 16 (20%)     | 18 (22.5%)       | 50 (20.83%)  |
| Lower middle                         | 24 (30%)     | 27 (33.75%)  | 26 (32.5%)       | 67 (27.92%)  |
| Upper Lower                          | 23 (28.75%)  | 22 (27.5%)   | 20 (25%)         | 65 (27.08%)  |
| Lower                                |              |              | , ,              | 05 (27.06%)  |
| LOWER                                | 0 (0%)       | 0 (0%)       | 0 (0%)           | U            |

Notes: All values presented as mean ± standard deviation (95% confidence interval) or number (percentage)

**Table II:** Intergroup comparison of bone pain by quantifying shin tenderness in terms of visual analogue score between Group A (correction after surgery) and Group B (correction before surgery) across all follow-ups using Kruskal-Wallis test. Visual Analog Scale for severity of shin tenderness.

| Follow-up duration | Visual Analog Scale for severity of shin tenderness |                   |          |  |
|--------------------|---|-------------------|----------|--|
|                    | Group A (na = 80)                                   | Group B (nb = 80) | p-value  |  |
| Pre-operative      | 7.06 ± 1.12   | 5.28 ± 1.32       | <0.0001  |  |
| 2 weeks            | 6.85 ± 1.06   | 5.11 ± 1.26       | < 0.0001 |  |
| 4 weeks            | 5.19 ± 1.21   | 3.13 ± 1.42       | < 0.0001 |  |
| 6 weeks            | 3.68 ± 1.04   | 1.06 ± 0.96       | < 0.0001 |  |
| 12 weeks           | $0.35 \pm 0.62$                                     | $0.33 \pm 0.5$    | 0.597    |  |

Notes: All values presented as mean ± standard deviation (95% confidence interval). P-value <0.05 is considered significant (bold).

SPSS software, version 21; SPSS Inc., [Chicago, IL, USA]. Longitudinal intragroup assessment of individual groups for improvement in VAS score for shin tenderness was done using repeated measure ANOVA test and pairwise comparison. The Kruskal-Wallis test was applied to compare the bone pain of each group with one another (Group A vs Group B vs Group C) at every follow-up. A power analysis of the study for a total sample size of 240 revealed a power score of 100% when keeping  $\sim$  as 0.05, and degree of freedom (df) as 2. Analysis for the sample size of each group as 80, keeping VAS score as the dependent variable, adjusted R squared as 0.340,  $\sim$  as 0.05, and df as 2 also revealed a power score of 100%.

# **RESULTS**

A total of 240 patients (n=240) were included in the study after matching, out of which 154 (64.17%) were females and 86 (35.83%) were males. The demographic data of the sample size was as elucidated in Table I. The mean age of the sample size was  $64.8\pm8.29$  years. The mean Vitamin D<sub>3</sub> levels of Group A at index consultation was  $16.8\pm6.08$ ng/ml while that of Group B was  $16.27\pm6.76$ ng/ml. The mean Vitamin D<sub>3</sub> levels of Group B after correction with three intramuscular injections of 600,000 IU Arachitol® in the preoperative period was  $51.02\pm6.45$ ng/ml.




Fig. 1: PRISM chart demonstrating recruitment protocol of the sample size and segregation into individual groups.

The VAS score for shin tenderness at second-week postoperative follow-up was insignificantly less as compared to the pre-operative VAS (p>0.05). The VAS score at 4 weeks, 6 weeks, and 12 weeks, however, was significantly better than the preceding follow-up and the pre-operative VAS (p<0.05) in all three groups (Table II). On intergroup comparison it was noted that Group B had similar VAS scores as compared to Group C throughout the follow-up period. Group B which underwent VDD correction prior to surgery had a significantly better VAS score (p<0.001) at the immediate pre-operative period. On post-operative follow-up at week two, week four and week six, Group B had statistically superior VAS score compared




Fig. 2: Flowchart representation of selection process of sample size, intervention process, and outcome assessment.

to Group A which underwent VDD correction after surgery (Table II). However, there was an improving trend in mean scores of Groups B as compared to Group A once correction of VDD was completed (Fig. 3). By the 12th week follow-up, both the groups that underwent VDD correction before and after surgery had comparable VAS score for shin tenderness (p=0.597). Mean serum Vitamin D levels repeated at 12 weeks follow-up showed similar values in

both groups (p=0.14). Group B had similar VAS score as compared to Group C throughout the follow-up period.

# **DISCUSSION**

Our study demonstrated that pre-operative diagnosis and correction of VDD (Vitamin D<sub>3</sub> <30ng/ml) by three, weekly, intramuscular injections of Arachitol® 600,000 units each, in




Fig. 3: Line diagram charting temporal trends of the three groups over the course of the follow-ups to compare the Mean Visual Analogue score for severity of shin tenderness.

patients planned for UKA gives excellent post-operative results. Role of supplementation of Vitamin D<sub>3</sub> deficiency prior to TKA surgery and its trends has been reported across literature, with no description of its influence on those undergoing UKA. The nutritional status of Vitamin D<sub>3</sub> is best reflected by the main circulating metabolite 25-Hydroxy Vitamin D<sub>3</sub> (25(OH)D<sub>3</sub>). Low levels of Vitamin D<sub>3</sub> have been reported in 22-36% of patients with Hip osteoarthritis by Bischoff-Ferrari *et al*<sup>18</sup> and up to 66% in patients with Knee osteoarthritis by Glowacki *et al*, as was the case in our study too<sup>19</sup>.

Type 2 muscle fibres have a greater amount of VDR's than type 1 muscle fibres therefore supplementation in deficient patients leads to the proliferation of type 2 muscle fibres<sup>20</sup>, consequently resulting in muscular development and function by regulating phosphate accumulation in the myocytes thereby aiding in muscle function as well<sup>21</sup>. This presumably explains improved bone pain and muscular strength after correction of VDD. Vitamin D<sub>3</sub> levels are directly linked to the articular cartilage thickness as well. It prevents cartilage loss through regulation of type 2 collagen, hence VDD has a deleterious effect on the articular cartilage thereby accelerating the progression of osteoarthritis<sup>22</sup>.

The demographic distribution of our sample size was similar to previous studies involving patients with MCOA of the knee joint as documented by Feng *et al* in 2019<sup>23</sup>. The prevalence of VDD in our sample size was 66% which was similar to the numbers reported by Song *et al*<sup>24</sup>. Injectable (IM) route of Vitamin D<sub>3</sub> supplementation was chosen in our study due to evidence of its efficacy, rapidity, and longevity of correction as opposed to oral supplementation which may take upto three months for correction<sup>18,25</sup>. Supplementation of VDD was done with 600,000 IU of IM Arachitol® injections

given at one-week intervals for three weeks, based on the experience of the authors. Toxicity was ruled out by looking for concerned signs and symptoms at every follow-up<sup>26</sup> and repeating the serum Vitamin D<sub>3</sub> levels at 12-week follow-up. Cut-off for hypervitaminosis D was 100ng/ml and toxicity was 150ng/ml as per the guidelines laid down by the Endocrine society and elucidated by Vogiatzi *et al* in 2014<sup>3</sup>. The mean Vitamin D<sub>3</sub> levels of the three groups remained well within therapeutic range on 12 weeks follow-up (Group A: 52.37±6.74; Group B: 50.48±6; Group C: 47.95±7.18).

Barker et al27 in their study reported deleterious effects of surgery in patients with insufficient Vitamin D<sub>3</sub> levels, while Maniar et al in 20169 assessed the negative impact of VDD on functional outcomes after a TKA. Similarly, we noted that supplementation of Vitamin D<sub>3</sub> pre-operatively significantly modulated post-operative bone pain by observing a better VAS score of shin tenderness in patients who underwent correction pre-operatively, which was similar to the group that had normal Vitamin D<sub>3</sub> levels to begin with. The findings of Maniar et al9 was also congruent to our study with respect to improvement of function on post-operative supplementation of Vitamin D<sub>3</sub>, however, unlike postoperative oral supplementation done in that study, we recommend pre-operative parenteral supplementation to safely expedite the correction process and minimise patient non-compliance.

Tomlinson *et al* in his study noted a significant increase in muscle strength when supplemented with Vitamin D<sub>3</sub>. Patients with deficient levels of Vitamin D<sub>3</sub> had higher odds of Hamstring strain compared with those with sufficient levels<sup>28</sup>. Similarly, we noted that supplementing the deficient groups improved the post-operative bone pain, muscle strength and exercise tolerance. Vitamin D<sub>3</sub> guideline put

forth by the National Osteoporosis Society states that those patients with an underlying bone disease that can potentially be improved with Vitamin D<sub>3</sub> supplementation or those who need Vitamin D<sub>3</sub> deficiency corrected prior to specific surgical intervention should have their Serum Vitamin D<sub>3</sub> levels measured pre-operatively<sup>29</sup>. The impact on the post-operative functional outcome is presumably related to Serum Vitamin D<sub>3</sub> levels as it modulates the inflammatory response. Hwang *et al*<sup>30</sup> reported in 2020 that pre-operative Vitamin D<sub>3</sub> levels does not affect short term functional outcome in elderly women after TKA. However, there is little to no evidence of the effect of the same in UKA.

This study helps in defining the role of Vitamin D3 deficiency as an important modifiable risk factor for postoperative bone pain even after a relatively bone and soft tissue conserving surgery like UKA. It advocates for routine inclusion of Serum Vitamin D3 levels as an important preoperative investigation before a UKA and preferably correction of any VDD before the surgery to give better postoperative results. The three groups were matched for age, gender, BMI, and dominance, thereby minimising any confounding effect in data collection. Other confounding factors to pain that were assessed included pre-operative demographic characteristics, patellofemoral involvement, deformity, psychosocial factors, deformity correction, impingement, infection, referred pain, malalignment, instability stiffness, impingement, implant loosening, speed and duration of mobilisation and rehabilitation. The clinicians as well as the diagnostic centres were blinded to patient data, hence eliminating bias. The authors acknowledge some limitations to the study. This study was done to evaluate the short-term effects of VDD in the immediate post-operative period and warrants for more research on the long-term effects of such corrections. The geographical area for the collection of the sample size was restricted and studies are required with a more diverse population pool to eliminate genetic and racial bias. A placebo or untreated group was not used for comparison and more studies incorporating the same could enhance external validity of the study. All the patients underwent only mobile bearing Oxford UKA, hence its effect on fixed bearing UKA cannot be extrapolated. All the patients were examined by a single, blinded clinician, thereby leaving a scope for human error. The study was conducted by a single surgeon and at a single centre, limiting the generalisability of the findings, hence we encourage more multicentric studies, with a more diverse, and larger sample size to validate our results. Finally, as all the procedures were done by a single surgeon, the reproducibility needs to be fortified by similar studies.

# **CONCLUSION**

With the trend shifting to unicompartmental knee arthroplasties in the patients with medial compartment osteoarthritis, the prevalence of Hypovitaminosis D seen in these individuals is also on a rise. We propose timely diagnosis of hypovitaminosis D (Serum Vitamin D<sub>3</sub> levels <30ng/ml) by including serum Vitamin D<sub>3</sub> levels as a routine pre-operative investigation and its requisite correction by administration of 600,000 IU of Arachitol® IM (three doses at an interval of one week each) in deficient patients pre-operatively for excellent post-operative control of bone pain and by extension, overall control of acute and recalcitrant pain in patients.

# **CONFLICT OF INTEREST**

The authors declare no potential conflict of interest.

# **REFERENCES**

- Miller JR, Dunn KW, Ciliberti LJ Jr, Patel RD, Swanson BA. Association of Vitamin D With Stress Fractures: A Retrospective Cohort Study. J Foot Ankle Surg. 2016; 55(1): 117-20. doi: 10.1053/j.jfas.2015.08.002
- 2. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr.* 2006; 84(1): 18-28. doi: 10.1093/ajcn/84.1.18
- 3. Vogiatzi MG, Jacobson-Dickman E, DeBoer MD; Drugs, and Therapeutics Committee of The Pediatric Endocrine Society. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. *J Clin Endocrinol Metab.* 2014; 99(4): 1132-41. doi: 10.1210/jc.2013-3655
- 4. Wacker M, Holick MF. Vitamin D effects on skeletal and extraskeletal health and the need for supplementation. *Nutrients*. 2013; 5(1): 111-48. doi: 10.3390/nu5010111
- 5. Baker PN, van der Meulen JH, Lewsey J, Gregg PJ; National Joint Registry for England and Wales. The role of pain and function in determining patient satisfaction after total knee replacement. Data from the National Joint Registry for England and Wales. *J Bone Joint Surg Br.* 2007; 89(7): 893-900. doi: 10.1302/0301-620X.89B7.19091
- 6. Chen KW, Chen CW, Yuan KC, Wang IT, Hung FM, Wang AY, *et al.* Prevalence of Vitamin D Deficiency and Associated Factors in Critically III Patients: A Multicenter Observational Study. *Front Nutr.* 2021; 8: 768804. doi: 10.3389/fnut.2021.768804
- Piuzzi NS, George J, Khlopas A, Klika AK, Mont MA, Muschler GF, et al. High prevalence and seasonal variation of hypovitaminosis D in patients scheduled for lower extremity total joint arthroplasty. Ann Transl Med. 2018; 6(16): 321. doi: 10.21037/atm.2018.08.21
- 8. Jansen JA, Haddad FS. High prevalence of vitamin D deficiency in elderly patients with advanced osteoarthritis scheduled for total knee replacement associated with poorer preoperative functional state. *Ann R Coll Surg Engl.* 2013; 95(8): 569-72. doi: 10.1308/rcsann.2013.95.8.569
- 9. Maniar RN, Patil AM, Maniar AR, Gangaraju B, Singh J. Effect of Preoperative Vitamin D Levels on Functional Performance after Total Knee Arthroplasty. *Clin Orthop Surg* 2016;8(2):153-6. doi:10.4055/cios.2016.8.2.153
- Lee A, Chan SKC, Samy W, Chiu CH, Gin T. Effect of Hypovitaminosis D on Postoperative Pain Outcomes and Short-Term Health-Related Quality of Life After Knee Arthroplasty: A Cohort Study. *Medicine (Baltimore)*. 2015; 94(42): e1812. doi: 10.1097/MD.000000000001812
- 11. Ong PH, Pua YH. A prediction model for length of stay after total and unicompartmental knee replacement. *Bone Joint J.* 2013; 95-B(11): 1490-6. doi: 10.1302/0301-620X.95B11.31193
- 12. Babaei M, Esmaeili Jadidi M, Heidari B, Gholinia H. Vitamin D deficiency is associated with tibial bone pain and tenderness. A possible contributive role. *Int J Rheum Dis.* 2018; 21(4): 788-95. doi: 10.1111/1756-185X.13253
- 13. Kennedy JA, Mohammad HR, Mellon SJ, Dodd CAF, Murray DW. Age stratified, matched comparison of unicompartmental and total knee replacement. *Knee*. 2020; 27(5): 1332-42. doi: 10.1016/j.knee.2020.06.004
- 14. Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, et al. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018; 2(3): e088. doi: 10.5435/JAAOSGlobal-D-17-00088
- 15. Gandek B, Ware JE Jr. Validity and Responsiveness of the Knee Injury and Osteoarthritis Outcome Score: A Comparative Study Among Total Knee Replacement Patients. *Arthritis Care Res (Hoboken)*. 2017; 69(6): 817-25. doi: 10.1002/acr.23193
- 16. Wani RT. Socioeconomic status scales-modified Kuppuswamy and Udai Pareekh's scale updated for 2019. *J Family Med Prim Care*. 2019; 8(6): 1846-9. doi: 10.4103/jfmpc.jfmpc\_288\_19
- 17. Lin W, Niu J, Dai Y, Yang G, Li M, Wang F. Mini-midvastus versus medial parapatellar approach in total knee arthroplasty: difference in patient-reported outcomes measured with the Forgotten Joint Score. *J Orthop Surg Res.* 2020; 15(1): 336. doi: 10.1186/s13018-020-01869-2
- 18. Bischoff-Ferrari HA, Zhang Y, Kiel DP, Felson DT. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. *Arthritis Rheum.* 2005; 53(6): 821-6. doi: 10.1002/art.21601

- 19. Glowacki J, Hurwitz S, Thornhill TS, Kelly M, LeBoff MS. Osteoporosis and vitamin-D deficiency among postmenopausal women with osteoarthritis undergoing total hip arthroplasty. *J Bone Joint Surg Am.* 2003; 85(12): 2371-7. doi: 10.2106/00004623-200312000-00015
- 20. Dawson-Hughes B. Vitamin D and muscle function. *J Steroid Biochem Mol Biol.* 2017; 173: 313-6. doi: 10.1016/j.jsbmb.2017.03.018
- 21. Dougherty KA, Dilisio MF, Agrawal DK. Vitamin D and the immunomodulation of rotator cuff injury. *J Inflamm Res.* 2016; 9: 123-31. doi: 10.2147/JIR.S106206
- 22. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med.* 2017; 5(6): 2325967117711376. doi: 10.1177/2325967117711376
- 23. Feng S, Yang Z, Sun JN, Zhu L, Wang S, Guo KJ, *et al.* Comparison of the therapeutic effect between the simultaneous and staged unicompartmental knee arthroplasty (UKA) for bilateral knee medial compartment arthritis. *BMC Musculoskelet Disord.* 2019; 20(1): 340. doi: 10.1186/s12891-019-2724-8
- 24. Song HR, Kweon SS, Choi JS, Rhee JA, Lee YH, Nam HS, *et al.* High prevalence of vitamin D deficiency in adults aged 50 years and older in Gwangju, Korea: the Dong-gu Study. *J Korean Med Sci.* 2014; 29(1): 149-52. doi: 10.3346/jkms.2014.29.1.149
- 25. Einarsdóttir K, Preen DB, Clay TD, Kiely L, Holman CD, Cohen LD. Effect of a single 'megadose' intramuscular vitamin D (600,000 IU) injection on vitamin D concentrations and bone mineral density following biliopancreatic diversion surgery. *Obes Surg.* 2010; 20(6): 732-7. doi: 10.1007/s11695-009-0024-3
- 26. Lim K, Thadhani R. Vitamin D Toxicity. J Bras Nefrol. 2020; 42(2): 238-44. doi: 10.1590/2175-8239-JBN-2019-0192
- 27. Barker T, Henriksen VT, Martins TB, Hill HR, Kjeldsberg CR, Schneider ED, *et al.* Higher serum 25-hydroxyvitamin D concentrations associate with a faster recovery of skeletal muscle strength after muscular injury. *Nutrients*. 2013; 5(4): 1253-75. doi: 10.3390/nu5041253
- 28. Tomlinson PB, Joseph C, Angioi M. Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis. *J Sci Med Sport.* 2015; 18(5): 575-80. doi: 10.1016/j.jsams.2014.07.022
- 29. Aspray TJ, Bowring C, Fraser W, Gittoes N, Javaid MK, Macdonald H, *et al.* National Osteoporosis Society vitamin D guideline summary. *Age Ageing*. 2014; 43(5): 592-5. doi: 10.1093/ageing/afu093
- 30. Hwang IY, Park KB, Chang SW, Cho SD, Youm YS. Preoperative vitamin D level does not affect the short-term functional outcome after total knee arthroplasty in elderly women. *Knee Surg Relat Res.* 2020; 32(1): 30. doi: 10.1186/s43019-020-00050-7

### Cite this article:

Rajani AM, Mittal ARS, Kulkarni VU, Rajani KA, Rajani KA. Role of Pre-operative Correction of Vitamin D3 Deficiency in Controlling Post-operative Bone Pain after Unicompartmental Knee Arthroplasty. *Malays Orthop J.* 2024; 18(3): xx-xx. doi: